Failure of Biologic Therapy in Psoriasis

CONCLUSION: The most common reason for discontinuing biologic therapy was that said therapy was not effective, though for ETA and UST, the fact that biologic therapies are not universally covered by insurance company was found to be associated with their discontinuation, as well. There were no statistically significant associations found between biologic therapy discontinuation and age, gender, or comorbidities, which last included obesity, class I. Larger studies are warranted to identify risk factors associated with biologic therapy failure to help guide drug selection, decrease morbidity associated with such nonadherence and improve patient outcomes.PMID:34543563

Source: Puerto Rico Health Sciences Journal - September 20, 2021 Category: International Medicine & Public Health Authors: Roc ío Cardona Natalia M Pelet Del Toro Eduardo Michelen-G ómez Gabriel E Arias-Berrios Rafael F Mart ín-García Source Type: research